Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Reconciliation of revenue from segments to consolidated

The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(In millions)	2026		2025		2026		2025
Total revenue	$	2,736.0	$	2,645.5	$	5,213.8	$	5,076.5
Less cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets:
Product cost of sales	582.3		415.0		1,061.0		877.2
Royalty cost of sales	194.6		190.0		376.9		357.1
Research and development:
Research and discovery	41.6		46.6		82.1		90.9
Early stage programs	49.3		51.9		118.3		124.3
Late stage programs	119.8		44.6		222.3		94.0
Marketed products	151.8		87.7		306.0		177.2
Other research and development costs(1)	167.1		168.2		339.9		346.7
Acquired in-process research and development, upfront and milestone expense	164.0		46.6		198.0		247.3
Selling, general and administrative	709.7		583.8		1,317.0		1,156.3
Other segment expense(2)	458.3		376.3		775.3		730.2
Net Income attributable to Biogen Inc.	$	97.5	$	634.8	$	417.0	$	875.3

(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.

(2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; other (income) expense, net; and income tax (benefit) expense